Mp45-11 Semaglutide Utilization in Weight Management and Its Implications for Urinary Tract Infections and Urolithiasis

You have accessJournal of UrologyStone Disease: Epidemiology & Evaluation II (MP45)1 May 2024MP45-11 SEMAGLUTIDE UTILIZATION IN WEIGHT MANAGEMENT AND ITS IMPLICATIONS FOR URINARY TRACT INFECTIONS AND UROLITHIASIS Anantha R. Soogoor, Pranjal Agrawal, Dianelis Pupo, Taylor P. Kohn, William Du Comb, and Mark N. Alshak Anantha R. SoogoorAnantha R. Soogoor , Pranjal AgrawalPranjal Agrawal , Dianelis PupoDianelis Pupo , Taylor P. KohnTaylor P. Kohn , William Du CombWilliam Du Comb , and Mark N. AlshakMark N. Alshak View All Author Informationhttps://doi.org/10.1097/01.JU.0001008764.86460.8e.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Semaglutide (Sg), a glucagon-like peptide-1 analog, initially indicated for the management of type 2 diabetes (DM), received FDA approval for the chronic management of weight in adults classified as obese or overweight with at least one obesity-related condition. While Sg has been studied extensively in the diabetic population, side effects in non-diabetic patients prescribed Sg for weight loss are still being investigated. Therefore, our study aims to analyze the association between UTIs and urolithiasis when Sg is used for weight loss management in a large national database. METHODS: We queried TriNetX Research, a claims and medical record research network of 79 healthcare organizations with more than 113 million patients, for those aged 18-60 years. Our control cohort included those with≥3 outpatient visits since June 1, 2021 (date of FDA approval for weight management) while excluding those with any Sg prescription (Rx). Our study cohort included those with≥3 outpatient visits since June 1, 2021, with first instance of Sg Rx after one of these outpatient visits. In addition, ≥3 Sg Rx were needed, with second Rx within 3 months of the first. Both cohorts excluded those deceased or with diagnosis of hyperparathyroidism, DM (corresponding diagnosis, A1c≥6.5%, insulin Rx, or metformin Rx ever). Propensity matching was done for age, race, sex, chronic kidney disease, overweight/obesity, sleep apnea, hypertensive diseases, and hyperlipidemia. Primary outcomes were urolithiasis or UTIs after initiation of Sg Rx. RESULTS: 19,089 patients meeting our study criteria were compared to an equivalent number of propensity-matched controls (Table 1). Compared to controls, patients with Sg Rx for weight management exhibited no increased susceptibility to urolithiasis (1.8% vs 1.9%, Risk Ratio (RR) 1.07, 95% Confidence Interval (CI) [0.92-.23]) and had lower risk of UTIs (2.2% vs 2.6%, RR 1.19, 95%CI [1.05-1.36]). CONCLUSIONS: In stark contrast to the considerable risks associated with UTIs and urolithiasis within the diabetic population, our investigation suggests that employing Sg for weight management in non-diabetics does not increase risk of urolithiasis and decreases risk of UTI. These findings add to the feasibility of Sg as a secure approach for weight management. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e746 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Anantha R. Soogoor More articles by this author Pranjal Agrawal More articles by this author Dianelis Pupo More articles by this author Taylor P. Kohn More articles by this author William Du Comb More articles by this author Mark N. Alshak More articles by this author Expand All Advertisement PDF downloadLoading ...